BACKGROUND: Breast cancer survivors experience long-term physical and psychological sequelae after their primary treatment that negatively influence their quality of life (QOL) and increase depressive symptoms. Group-based cognitive-behavioral stress management (CBSM) delivered after surgery for early-stage breast cancer was previously associated with better QOL over a 12-month follow-up and with fewer depressive symptoms up to 5 years after study enrollment. This 8-to 15-year follow-up (median, 11 years) of a previously conducted trial (NCT01422551) evaluated whether women in this cohort receiving CBSM had fewer depressive symptoms and better QOL than controls at an 8-to 15-year follow-up. METHODS: Women with stage 0 to IIIb breast cancer were initially recruited 2 to 10 weeks after surgery and randomized to a 10-week CBSM intervention or a 1-day psychoeducational control group. One hundred women (51 CBSM patients and 49 controls) were recontacted 8 to 15 years after study enrollment to participate in a follow-up assessment. The Center for Epidemiologic Studies-Depression (CES-D) scale and the Functional Assessment of Cancer Therapy-Breast (FACT-B) were self-administered. Multiple regression was employed to evaluate group differences on the CES-D scale and FACT-B over and above effects of confounding variables. RESULTS: Participants assigned to CBSM reported significantly lower depressive symptoms (d, 0.63; 95% confidence interval [CI], 0.56-0.70) and better QOL (d, 0.58; 95% CI, 0.52-0.65) above the effects of the covariates. CONCLUSIONS: Women who received CBSM after surgery for early-stage breast cancer reported lower depressive symptoms and better QOL than the control group up to 15 years later. Early implementation of cognitive-behavioral interventions may influence long-term psychosocial functioning in breast cancer survivors.
INTRODUCTION
Cancer survivors constitute approximately 4% of the United States population (13.7 million) as of 2012, 1 with 40% having survived 10 or more years. 2 Approximately 22% of these are female breast cancer survivors, and this makes these survivors the most prevalent cancer survivor group. 2 Medical advances that have extended survival and lowered recurrence rates in breast cancer also bring persistent side effects and emotional sequelae into the posttreatment period. Fatigue, insomnia, depression, cognitive dysfunction, and menopausal symptoms are among the commonly reported difficulties of breast cancer survivors, 3 and they are compounded by fears and stress concerning the possibility of recurrence. 4 Breast cancer survivors report difficulty in quality of life (QOL) domains of physical and emotional/psychological well-being. 5 Lower scores on physical QOL domains are attributed to ongoing pain, swelling, fatigue, and treatmentinduced menopausal symptoms 6 ; lower scores on emotional/psychological QOL domains are attributed to worries about recurrence. 6 Long-term (>5-year) breast cancer survivors report a higher prevalence of mild to moderate depressive symptoms than healthy controls, 5 with prevalence rates of at least 15% at 5 years after their diagnosis 7 versus rates of 4.5% to 9.3% for women in health community samples. 8 Psychosocial interventions based on cognitive-behavioral theories are most commonly used to improve QOL in cancer populations. 9 Meta-analyses have found them efficacious in improving QOL and depressive symptoms in the short term, but less is known about long-term effects. [10] [11] [12] Cognitive-behavioral stress management (CBSM) delivered postsurgically for women with early-stage breast cancer has been shown to improve QOL 13 and reduce depressive symptoms up to 5 years after treatment. 14, 15 More research is needed to determine whether women who receive CBSM as they move through active treatment experience even longer term benefits. This study aimed to evaluate whether women who received 10 weeks of groupbased CBSM 2 to 10 weeks after surgery for early-stage breast cancer would report lower depressive symptoms and better QOL than women in the control group at an 8-to 15-year follow-up (median, 11 years).
MATERIALS AND METHODS

Patients and Study Design
Participants came from a single-center, single-blind, randomized, parallel assignment efficacy trial approved by the institutional review board of the University of Miami and conducted between 1998 and 2005. Women who were 2 to 10 weeks after surgery for stage 0 to IIIb breast cancer were recruited via physician referrals from private practices and the Sylvester Cancer Center as well as advertising. Women were excluded if they had stage IV breast cancer, had begun adjuvant treatment, had been previously diagnosed with another serious cancer, had other major medical conditions, had been diagnosed with psychosis or panic disorder, had endorsed suicidality, were not between the ages of 21 and 75 years, or were not fluent in English.
Of the 502 potential participants screened, 106 did not meet the inclusion criteria, and 156 declined participation; 240 signed informed consents, were enrolled, and completed a baseline assessment, including intervieweradministered and self-report psychosocial questionnaires. Women were then randomly assigned to either a 10-week group-based CBSM intervention or a 1-day group-based psychoeducational seminar control. Randomization was implemented on a 1:1 basis. Each cohort averaged approximately 14 participants. Blinded study coordinators conducted randomization and assessments. Each group was coded by a PhD-level clinical psychologist and a graduate student in clinical psychology. Assessments were repeated 6 months, 12 months, and 5 years after study enrollment.
Details of the parent study (National Institutes of Health Clinical Trial NCT01422551) are fully described in initial interim reports 13 and recent reports with the final sample. 16 The parent study found that breast cancer survivors in the CBSM condition reported lower depressive symptoms and better QOL than controls at the 3 follow-up time points.
We launched a new study in 2013 to assess depressive symptoms and QOL in a longer term follow-up of survivors from this cohort. Participants, now 8 to 15 years after enrollment (median, 11 years), were recontacted to complete questionnaires assessing QOL, depressive symptoms, and medical status. This article reports findings from this 8-to 15-year follow-up. From the original sample of 240 patients, 20 had requested no further contact, 30 were confirmed to be deceased at this follow-up, we were unable to locate a new address or phone number for 2, 1 was contacted but declined to participate, 25 agreed to participate but did not return the packet after multiple requests, and 62 were unreachable or lost to follow-up (see the Consolidated Standards of Reporting Trials flow diagram for an illustration of participation from the time of contact for the original trial through the present followup; Fig. 1 ). One hundred participants (CBSM group, 51; control group, 49) returned the questionnaires.
Intervention Condition
The initial study tested a manualized CBSM intervention 17 designed to improve coping and psychosocial adaptation and to reduce stress and negative mood for women undergoing primary breast cancer treatment. This intervention comprises cognitive-behavioral therapy (eg, cognitive reframing, effective coping skills training, assertiveness training, and anger management) and relaxation training (eg, progressive muscle relaxation, guided visual imagery, and diaphragmatic breathing).
Control Condition
The control group was a 1-day psychoeducational selfhelp classroom seminar that took place within the corresponding 10-week intervention period. Women were given general information about breast cancer care and health. A condensed version of select portions of the CBSM modules came in handouts, but women did not have opportunities to practice those techniques.
Measures
Depression
Depressive symptomatology within the past week was assessed at this follow-up with the Center for Epidemiologic Studies-Depression (CES-D) scale. 18 The CES-D scale contains 20 items (eg, "I felt hopeless about the future"), with responses ranging from rarely or none of the time (0) to most or all of the time (4). After appropriate reverse coding, responses were summed for a total score (possible range, 0-60). Higher total scores indicated more symptomatology. Reliability was good in the present sample (a 5 .90).
QOL
The self-administered, 44-item Functional Assessment of Cancer Therapy-Breast (FACT-B) 19 was used to assess participants' overall QOL, including specific breast cancer physical concerns (eg, "I have a lack of energy") and emotional concerns (eg, "I worry about dying"). Response possibilities ranged from not at all (0) to very much (4). After appropriate reverse coding, items were summed for a total score (possible range, 0-164), with higher scores indicating better QOL. Because much of the research on breast cancer focuses specifically on physical and emotional well-being subscales, 5, 6 we also analyzed those separately. The a values for the FACT-B, Physical Well-Being scale, and Emotional Well-Being scale in the present sample were .94, .84, and .79, respectively.
Medical and Demographic Characteristics
Self-reported demographic, socioeconomic, medical, and breast cancer treatment information was collected at the baseline, 6 months, and 12 months. Information related to the breast cancer diagnosis, recurrence, and treatment was collected again at the follow-up and verified with medical chart reviews.
Statistical Analyses
Multiple regression was conducted with the Statistical Package for the Social Sciences (version 19) to examine whether the study condition was associated with QOL on the FACT-B total, Physical Well-Being scale, and Emotional Well-Being scale and with depressive symptoms on the CES-D scale at the 8-to 15-year follow-up over and above the effects of confounding predictors.
Highly skewed or kurtotic variables were logtransformed to meet assumptions of normality. Three outliers on the FACT-B and 1 outlier on the CES-D scale were Winsorized to fall within 3 standard deviations of the mean. 20 All analyses controlled for baselines of the comparable measure of well-being: analyses of QOL controlled for initial QOL as assessed by the FACT-B, and analyses of depressive symptoms controlled for initial scores on the Hamilton Depression Rating Scale. 21 An a priori set of covariates was established with the criteria that they differed by the study condition at the baseline or had been shown to affect QOL and depressive symptoms. 22, 23 Controlled were income, 5 race/ethnicity (each minority vs white as a dummy code), 24 body mass index, 25 antidepressant use, 26 endocrine therapy, 27 and disease recurrence status. 28 In 2 more cases, potential control variables were highly correlated (menopausal status with age and stage with surgical procedure). To minimize the number of covariates, 22 only 1 of the 2 from each pair was retained (age and surgical procedure).
This set of covariates was entered into the initial step of the hierarchical model; the treatment condition was entered into the second step. Standardized regression coefficients at a 2-tailed level of significance (P < .05), 95% confidence intervals (CIs), and corresponding effect sizes (0.20, small; 0.50, medium; and 0.80, large) 29 were used to assess the relationships between study conditions and outcomes. Table 1 displays demographic and medical characteristics by the study condition. At this follow-up, the breast cancer survivors were 62.47 years old on average (standard deviation, 8.99 years). Most were non-Hispanic white (70%), which was followed by Hispanic (21%), black (5%), and Asian (3%). Twelve had experienced breast cancer recurrence. The study conditions were equivalent for all characteristics except age, menopausal status, and surgical procedure (lumpectomy vs mastectomy).
RESULTS
Participant Characteristics
Women who completed questionnaires at this time point (n 5 100) were not different from women in the initial trial who did not (n 5 140) with respect to condition assignment (ie, CBSM vs control; v Table 2 Breast cancer survivors who had been assigned to CBSM also reported significantly lower depressive symptoms at follow-up (mean, 4.69; SE, 1.74) than those assigned to the control group (mean, 10.10; SE, 1.57; d, 0.63; 95% CI, 0.56-0.70); this constituted a mediumlarge effect size ( Table 3 ). The full model explained 37% of the variance in depressive symptoms (P 5 .040). The current sample size was sufficient to detect an effect of medium magnitude with 95% power.
DISCUSSION
This is the first study to examine long-term psychosocial effects in a randomized controlled trial of group-based CBSM at an 8-to 15-year follow-up in breast cancer survivors. Women who received CBSM in the weeks following surgery reported better QOL and lower depressive symptoms than women in the control group 8 to 15 years later. Women in the CBSM intervention group also reported better physical and emotional well-being. These findings suggest that women given the opportunity to learn stress management (relaxation training and cognitive-behavioral techniques) during active treatment may benefit well into survivorship. Group differences in QOL and depressive symptoms were found over and above effects of confounding demographic, medical, and cancer treatment-related predictors. The CIs and medium-to-large effect sizes suggest that the magnitude of the group differences in QOL and depressive symptoms are clinically significant.
Although studies have examined long-term psychosocial well-being among breast cancer survivors, very few Original Article have evaluated the long-term influence of a psychosocial intervention on these outcomes of well-being. 30 A study by Helgeson et al 31 found that women given an 8-week educational intervention for early-stage breast cancer continued to show improved QOL up to 3 years after the intervention. A meta-analysis, using a median follow-up length less than or greater than 8 months, concluded that cognitive-behavioral therapy was effective in the short term for QOL and depression among cancer survivors, whereas long-term effects were found only for QOL. 12 This highlights the need to treat longterm depressive symptoms, which are still prevalent at least 6 to 13 years after treatment in breast cancer survivors. One previous study found a mean CES-D score of 10.5 among breast cancer survivors 1 or more years after treatment, whereas age-and sex-matched controls reported a mean of 8.3. 33 Women in our control group reported a mean CES-D score of 10.10 and resembled breast cancer survivors from that study, whereas the mean CES-D score in the CBSM group (mean, 4.69) was significantly lower than scores among healthy controls [t(276) 5 3.47, P 5 .001] and breast cancer survivors [t(242) 5 4.52, P < .0001].
32
Group-based cognitive-behavioral interventions in early-stage breast cancer reduced depressive symptoms up to 1 to 2 years after treatment. 34 Previous research showed that women receiving CBSM after surgery for early-stage breast cancer reported lower depressive symptoms than a control group at the 1-and 5-year follow-ups. 14, 15 The present study extends these findings to 8 to 15 years after treatment and suggests that a psychosocial intervention may affect long-term depressive symptomatology.
With respect to FACT-B QOL, a natural history study among women more than 5 years after treatment 35 reported a physical well-being mean (mean, 24.30) that is comparable to the mean for our control group, whereas our CBSM group members reported significantly higher physical well-being [mean, 27.14; t(86)5 2.54; P 5 .013]. A similar, though less pronounced pattern was evident for FACT-B Emotional Well-Being scores, whereby the CBSM group showed greater QOL (mean, 22.49) than scores observed in the natural history sample [mean, 18.0, t(86) 5 5.31, P < .0001], although our controls revealed scores falling between these 2 values (mean, 20.34). In summary, women in the CBSM group had QOL scores higher than other breast cancer survivors in observational studies. 35 This suggests that CBSM can provide a buffer against deterioration in QOL throughout survivorship.
Specific therapeutic components of CBSM may be pathways for these long-term effects. Relaxation training increases confidence in relaxation skills, 13, 36 which may encourage their use as a coping modality after treatment and, in turn, lower distress. Cognitive restructuring and adaptive coping aspects of CBSM address cancer-specific distress around fears of recurrence and disease progression. Women may also continue to use these coping skills after treatment cessation to manage fears of recurrence; this, in turn, may ameliorate depressive symptoms and improve QOL.
Strengths and Limitations
The extended follow-up period in this study is notable because most studies examining psychosocial functioning in breast cancer survivors employ much shorter follow-up times. 12 Rather than examine only disease-free breast cancer survivors, the present study reports QOL and depressive symptoms among both women who remained disease-free and women who experienced recurrence. Approximately one-third of the current sample was of an ethnic minority (ie, Black, Hispanic, or Asian), and this increased the generalizability of the findings to women of various ethnic backgrounds. However, generalizability is limited by other factors, such as the academic setting in which the study took place, the geographical location, the early-stage sample, and the observed differences between women who took part in the follow-up and those who did not. The fact that women who participated in the followup were older and reported fewer depressive symptoms and greater well-being at the time of diagnosis than women who did not participate should be considered when these findings are generalized to all breast cancer survivors. A self-report bias may play a role in the measures collected. Because of the post hoc nature of this follow-up study, the sample size was lower than that of the original starting sample, with 42% of the originally randomized sample taking part. Future work should seek to understand the mechanisms by which CBSM produces these long-term effects.
Clinical Relevance
This study has clinical implications because of the high prevalence of long-term depressive symptoms and diminished physical and emotional QOL in breast cancer survivors. [5] [6] [7] Depression in breast cancer survivors is a major health concern because it is a significant source of emotional distress and impaired physical and social functioning. In breast cancer survivors, depression is highly associated with pain, fatigue, and insomnia. 32 Furthermore, depression is an established risk factor for noncompliance with medical treatment. 37, 38 Noncompliance with follow-up visits and with long-term regimens such as hormonal therapy may explain poorer clinical outcomes for depressed breast cancer patients. 39 Cancer care plans outline the importance of ongoing evaluations of psychosocial burden and symptom management throughout breast cancer survivorship. 35, 40 In conclusion, this 8-to 15-year follow-up of a randomized controlled trial in women with early-stage breast cancer showed that participants who received a 10-week, group-based CBSM intervention reported fewer depressive symptoms and better QOL than women in the control group. The current findings highlight the possibility of maintaining long-term psychosocial health by way of early psychosocial intervention.
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